Compare Ascendis Pharma A/S (ASND) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Illinois Tool Works Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Illinois Tool Works Inc. trades at $269.23 (market cap $77.34B). The key difference: Illinois Tool Works Inc. is far larger — about 4.4× Ascendis Pharma A/S's market cap, and Illinois Tool Works Inc. pays a 2.4% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ITW | |
|---|---|---|
Market Cap | $17.74B | $77.34B |
Sector | Health | Industrials |
52-Week High | $277.18 | $299.60 |
52-Week Low | $163.32 | $241.07 |
Enterprise Value | $18.11B | $85.66B |
Dividend Yield | — | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ITW trades at $268.81, up 1.25% with a bullish technical signal and strong profitability metrics including 19.32% net margin and 96.88% ROE. Recent earnings beats and a $1.61 dividend payment reflect operational strength, though cash flow trends show slight volatility. The stock is near resistance at $268 with analyst consensus target of $284.50.
Outlook remains positive with consistent earnings outperformance and margin expansion from enterprise initiatives. Risks include construction sector weakness and currency exposure. Wall Street shows mixed sentiment with 21% buy ratings, suggesting cautious optimism amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
